MetaCap

SI-BONE Inc. (SIBN)

NASDAQ: SIBNHealth CareMedical/Dental InstrumentsUSD

23.73-0.02 (-0.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SIBN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.31
52-week range
11.48 – 25.92
Day range
23.54 – 24.40
Volume / Avg
800.98K / 709.79K
Beta
—

52-week range

$11.48$25.92

SIBN stock today

SI-BONE (SIBN) closed at $23.73 on Nov 20, down 0.08% (-$0.02), versus the S&P 500's 3.70% decline. At this level, SIBN sits near the top of its 52-week range of $11.48 to $25.92: 8.4% below the high, set on Nov 4, 2026 and 106.7% above the low. SIBN is up 20.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.7%.

SI-BONE has posted a net loss over the last twelve months (EPS of -$0.31), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About SI-BONE

Company profile

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.

Industry
Medical/Dental Instruments
CEO
Ms. Laura A. Francis MBA
Headquarters
Santa Clara, CA
Employees
376
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, SI-BONE generated $200.9 million in revenue, up 20.2% from fiscal 2024, its 8th consecutive year of revenue growth. SI-BONE reported a net loss of $18.9 million, compared with a loss of $30.9 million a year earlier. Gross margin was 79.6% (up from 79.0%) and operating margin -11.1%.

SI-BONE annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$200.93M$167.18M$138.89M$106.41M$90.15M
Growth+20.19%+20.37%+30.52%+18.03%+22.84%
Net income$-18.90M$-30.91M$-43.34M$-61.26M$-56.57M
EPS (diluted)$-0.44$-0.75$-1.13$-1.79$-1.71

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$26.78+12.85%

  • Strong buy 3
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $23.00High $32.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$-0.11 vs $-0.13
Surprise
+15.38%

SIBN news

All SIBN news

SI-BONE peers

Health Care sector
SIBN peer companies
CompanyPrice% ChgMarket capCompare
DRTSAlpha Tau Medical Ltd.11.76+3.93%$1.09Bvs SIBN
IRMDiRadimed Corporation81.02-0.30%$1.04Bvs SIBN
IARTIntegra LifeSciences Holdings Corporation13.25-2.21%$1.03Bvs SIBN
ATECAlphatec Holdings Inc.6.68-3.19%$1.02Bvs SIBN
SGPSpyGlass Pharma Inc.30.43-1.14%$1.02Bvs SIBN
TNDMTandem Diabetes Care Inc.17.46+3.93%$1.22Bvs SIBN
NVCRNovoCure Limited10.71+0.19%$1.25Bvs SIBN
AORTArtivion Inc.18.16-2.00%$886.02Mvs SIBN

Indexes, lists and sector

SI-BONE stock FAQ

What is SI-BONE's stock price today?

SIBN last traded at $23.73 as of Nov 20, 4:00 PM EST, down 0.08% on the day. Prices are delayed at least 15 minutes.

Who is SI-BONE's CEO?

Ms. Laura A. Francis MBA is the chief executive officer of SI-BONE Inc., which has about 376 employees.

What is the SIBN 52-week high?

The 52-week high for SIBN is $25.92 and the 52-week low is $11.48. The stock is currently 8.4% below its high.

Compare SIBN